Evidence map›Paper›PMID 27491641›Full record

Trial reportLeukemia2017

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.

P Moreau, D Joshua, W-J Chng, A Palumbo, H Goldschmidt, R Hájek, T Facon, H Ludwig, L Pour, R Niesvizky and 12 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01568866 (A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma), which is not on this map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01568866 phase3completednot on this map

A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

TypeinterventionalSponsorAmgenRan2012 to 2018Enrolled929ConditionsMultiple MyelomaArmsCarfilzomib, Bortezomib, Dexamethasone
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Review
  14. Article
  15. An Update of the Appropriate Sequencing for Salvage Therapies in Multiple Myeloma.Mediterranean journal of hematology and infectious diseases · 2025
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 17 institutions in 12 countries.

P MoreauUniversity of Nantes, Nantes, France.
D JoshuaRoyal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
W-J ChngNational University Cancer Institute, National University Health System; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
A PalumboUniversity of Torino, Torino, Italy.
H GoldschmidtHeidelberg Medical University, Heidelberg, Germany.
R HájekUniversity Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
T FaconCHRU Lille Hôpital Claude Huriez, Lille, France.
H LudwigWilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.
L PourUniversity Hospital Brno, Brno, Czech Republic.
R NiesvizkyWeill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA.
A OriolInstitut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
L RosiñolHospital Clínic de Barcelona, Barcelona, Spain.
A SuvorovHematological Department, First Republican Clinical Hospital of Udmurtia, Izhevsk, Russia.
G GaidanoDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
T PikaDepartment of Hematooncology, University Hospital Olomouc, Olomouc, Czech Republic.
K WeiselUniversitätsklinikum Tübingen, Tübingen, Germany.
V Goranova-MarinovaUniversity Multiprofile Hospital for Active Treatment 'Sv. Georgi' and Medical University, Plovdiv, Bulgaria.
H H GillenwaterOnyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
N MohamedOnyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
S AggarwalOnyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
S FengOnyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
M A DimopoulosNational and Kapodistrian University of Athens, Athens, Greece.
Amgen (United States) · USHôpital Claude Huriez · FRHospital Clínic de Barcelona · ESInstitut Català d'Oncologia · ESMedical University Plovdiv · BGNantes Université · FRNational and Kapodistrian University of Athens · GRNational University Cancer Institute, Singapore · SGNew York Hospital Queens · USRoyal Prince Alfred Hospital · AUThe First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic · RUUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversitätsklinikum Tübingen · DEUniversity Hospital Brno · CZUniversity Hospital Olomouc · CZUniversity Hospital Ostrava · CZWilhelminen Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with ⩾2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (⩾2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneDisease-Free SurvivalHumansMiddle AgedMultiple MyelomaOligopeptidesRecurrenceSalvage TherapyTreatment OutcomeBortezomibcarfilzomibDexamethasoneOligopeptides

Identifiers

PMID27491641
PMCPMC5220137
OpenAlexW2465965969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.